Loading...

XFOR X4 PHARMACEUTICALS INC Product Launches 8-K Filing

X4 P

XFR

X4 PHARMACEUTICALS INC

(XFOR)

2024 8-K

Summary

Summary

Company Restructuring

Financing Announcement

Equity Offerings

Financial Statements

Stock Split Approval

Financial Results

Nasdaq Compliance

Strategic Restructuring

New Licensing Agreement

Positive Trial Results

Financial Results

Regulation FD Disclosure

Results of Operations and F...

Regulation FD Disclosure

Clinical Data Announcement

Annual Meeting Results

Regulation FD Disclosure

Results of Operations and F...

Regulation FD Disclosure

FDA Approval of XOLREMDI Ca...

Compliance with Nasdaq's bi...

Regulation FD Disclosure

Results of Operations and F...

Regulation FD Disclosure

Regulation FD Disclosure

Earnings Reports

FDA Accepts NDA for Mavorix...

Appointment of Director

Earnings Reports

Loan Agreement Amendment

Annual Meeting Results

Regulation FD Disclosure

Private Placement

Investor Conferences

Earnings Reports

Earnings Reports

Regulation FD Disclosure

Financial Results Announcement

Disinvestment of Assets

Regulation FD Disclosure

External Links:

X4 Pharmaceuticals announced positive results from a six-month Phase 2 trial of mavorixafor for chronic neutropenia, showing significant increases in neutrophil counts and reduced need for G-CSF treatment.

AI Assistant

X4 PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.